Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1.

Abstract

OBJECTIVE:

The objective of our study was to show the efficacy and safety of percutaneous ethanol ablation in managing recurrent primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN1) after subtotal parathyroidectomy.

CONCLUSION:

Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1.

• Authors: Mark W Veldman, Carl C Reading, Michael A Farrell, Brian P Mullan, Robert A Wermers, Clive S Grant, Geoff B Thompson
• Journal: AJR. American journal of roentgenology (AJR Am J Roentgenol) Vol. 191 Issue 6 Pg. 1740-4 (Dec 2008) ISSN: 1546-3141 [Electronic] United States
• PMID: 19020245 (Publication Type: Journal Article)

Chemical References

• Ethanol

Topics

• Adult
• Aged
• Ethanol (administration & dosage)
• Humans
• Hyperparathyroidism (therapy)
• Injections, Subcutaneous
• Middle Aged
• Multiple Endocrine Neoplasia Type 1 (therapy)
• Neoplasm Recurrence, Local (therapy)
• Parathyroid Neoplasms (therapy)
• Retrospective Studies
• Treatment Outcome